Scottish Medicines Consortium

Scotland backs rare blood cancer drug Poteligeo rejected by NICE

https://pharmaphorum.com/news/scotland-backs-rare-blood-cancer-drug-poteligeo-rejected-by-nice/

Double first for Scotland as it backs Roche’s Rozlytrek, Novartis’ Zolgensma

https://pharmaphorum.com/news/double-first-for-scotland-as-it-backs-roches-rozlytrek-novartis-zolgensma/

Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancer

https://pharmaphorum.com/news/scotland-backs-merck-pfizers-bavencio-combo-for-kidney-cancer/

After a nay from NICE, Scotland says aye to J&J’s Spravato

https://pharmaphorum.com/news/after-a-nay-from-nice-scotland-says-aye-to-jjs-spravato/

Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenance

https://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/

Keeping up the PACE at the Scottish Medicines Consortium (SMC)

https://pharmaphorum.com/views-analysis-market-access/keeping-up-the-pace-at-the-scottish-medicines-consortium-smc/

Pfizer’s Ibrance available across UK after thumbs up in Scotland

https://pharmaphorum.com/news/ibrance-available-across-uk-scottish/

Eisai bemoans UK’s north-south cancer divide

https://pharmaphorum.com/news/eisai-bemoans-north-south-thyroid-cancer-divide/

Imbruvica, Opdivo and Praluent gain approvals for Scotland’s NHS

https://pharmaphorum.com/news/imbruvica-opdivo-praluent-gain-approvals-scotlands-nhs/

Close in 10 seconds

Pharmaphorum.com

Search